Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.

Slides:



Advertisements
Similar presentations
Contemporary practice of radiotherapy post radical prostatectomy at a tertiary referral centre in Australia Introduction  Adverse features on histopathology.
Advertisements

Prostate Cancer What a GP Needs to Know
Is Radical Prostatectomy Adequate For High Risk Prostate Cancer?
PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.
Rising PSA after Radical Prostatectomy. My Approach. Dr Manish Patel Urological Cancer Surgeon Urological Cancer Surgeon Westmead Hospital University of.
Advanced Stage Prostate Cancer Management Michael E. Karellas Assistant Professor of Urologic Oncology May 15, 2010.
Management of locally advanced & metastatic prostate cancer Dr. Purvish. M. Parikh MD, DNB, PhD, FICP Professor & Head Department of Medical Oncology Tata.
Introduction Treatment of metastatic prostate cancer with androgen deprivation therapy (ADT) is effective, but can be associated with debilitating side.
Continuous versus Intermittent Androgen Deprivation Therapy for Prostate Cancer Robert Dreicer, M.D., M.S., FACP, FASCO Chair Dept of Solid Tumor Oncology.
3D Prostate Mapping Biopsies
Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.
Advances in the Management of Skeletal Related Events/Bone Metastases in Prostate Cancer Robert Dreicer, M.D., M.S., FACP, FASCO Chair Dept of Solid Tumor.
Steven Joniau Filip Ameye
Management of Prostate Cancer Post-Prostatectomy
Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.
PROGRESS IN MANAGEMENT OF PROSTATE CANCER Presented by Dr. J. Nkusi on the October 2007, 38 th Congress of the Botswana Medical Association.
Prostate Cancer Int. 洪 毓 謙. Prostate cancer is the Second leading cause of death from cancer in the United States American male, the lifetime risk of:
M. Wirth Department of Urology, Technical University of Dresden Adjuvant or Salvage Radiotherapy after Radical Prostatectomy.
Treatment options for locally recurrent Prostate Cancer Giuseppe Simone Mediterranean School of Oncology Roma
Prostate cancer: To screen or not to screen – To treat or not to treat Dr Oliver Klein – Medical Oncologist.
Howard M. Sandler, MD University of Michigan Medical School
Long-term follow-up of a prospective trial of pre-operative external-beam radiation and post-operative brachytherapy for retroperitoneal sarcoma LA Mikula,
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Douglas S. Scherr, M.D. Assistant Professor of Urology
Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.
Mark L. Merlin, M.D. Radiotherapy Clinics of Georgia 7/14/2010 The Role of Radiation Therapy in the Management of Prostate Cancer.
Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.
Design of Clinical Trials for Select Patients With a Rising PSA following Primary Therapy Anthony V. D’Amico, MD, PhD Professor of Radiation Oncology Harvard.
Updated 5-year Biochemical Relapse-Free Survival after Prostate Brachytherapy Jenny P. Nobes St. Luke’s Cancer Centre, The Royal Surrey County Hospital,
HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF.
PROSTATE CANCER: RADIATION THERAPY APPROACHES ANDREW L. SALNER, MD FACR DIRECTOR HELEN & HARRY GRAY CANCER CENTER HARTFORD HOSPITAL, CT.
Protocols for Advanced Prostate Cancer and/or Local Failure After Radical Prostatectomy Isaac Powell, MD.
Predicting Subsequent Response to Hormone Therapy Following First-line Androgen Deprivation in Advanced Prostate Cancer S. Turner H. Gurney V. Gebski M.
Robert Dreicer, M.D., M.S., FACP Chair Dept of Solid Tumor Oncology
Prostate Cancer: Treatment choices Prostate Cancer: Treatment choices Winston W Tan MD FACP Winston W Tan MD FACP Senior Consultant Senior Consultant Genitourinary.
Prostate Cancer Screening Risk Management Ben Inch.
FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,
Hormone treatment combined with radiotherapy
High Dose Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian 1, Vivian Weinberg 3, Joycelyn.
Combined Modality Treatment of Locally Advanced Prostate Cancer: Radiation Therapy (RT) with Concurrent Androgen Deprivation Therapy (ADT) Howard Sandler.
SC-PM6: Prediction Models in Medicine: Development, Evaluation and Implementation Michael W. Kattan, Ph.D. Ewout Steyerberg, Ph.D. Brian Wells, M.S., M.D.
Postsurgical Risk Factors for Prostate Cancer Mortality Slideset on: Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality.
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.
Debra Freeman, MD – Naples Christopher King, MD, PhD - Stanford.
Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.
Journal Club August 10, 2012 Ryan M. Zitnay MD. Case 71 y/o male veteran w PMH CAD s/p MI, HTN, HL, constipation Followed by urology for rising PSA x.
Matthew Raymond Smith, MD, PhD Professor of Medicine Harvard Medical School Program Director, Genitourinary Oncology Massachusetts General Hospital Cancer.
Radiation therapy for Early Stage Prostate Cancer
Surgical Treatment in Locally Advanced Prostate Cancer
STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
Bladder Cancer and Prostatic Cancer
CCO Independent Conference Coverage
Decipher Prostate, Decipher Bladder and Decipher GRID
N.N. Alexandrov National Cancer Centre
Prostate Cancer: Highlights from 2006
Claude C. Schulman, Jacques Irani, Juan Morote, Jack A
What is New in Hormone Therapy for Prostate Cancer in 2007?
Volume 67, Issue 6, Pages (June 2015)
Localised and Locally Advanced Prostate Cancer: Who to Treat and How?
Volume 64, Issue 6, Pages (December 2013)
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Risk Factors for the Development of Bone Metastases in Prostate Cancer
Radiation Therapy for Prostate Cancer
What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006  Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,
Long-Term Hormonal Therapy: Who Would Benefit?
Highlighting Unmet Needs: Real Patients, Difficult Choices
Role for XRT in treatment of early stage Follicular lymphoma?
Management of Prostate Cancer: Global Strategies
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Presentation transcript:

Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center Duke Prostate Center Duke Cancer Institute Duke University School of Medicine

Treatment Options for PSA Failure Observation Local therapy – post-surgery ◦External beam radiation ◦Brachytherapy (rare) Local therapy – post-radiation ◦Cryotherapy? ◦Repeat radiation? ◦Surgery? Systemic ◦Hormonal therapy ◦Role of chemotherapy?

Role of Imaging in PSA Failure Is the failure local or systemic? Imaging ◦Pelvic CT – limited role in low PSA ◦Bone scan – usually negative if PSA <10 ng/ml ◦ProstaScint ® – low sensitive and specificity May be more helpful post radiation Typically treat empirically

Risk of Prostate Cancer-Specific Mortality (PCSM) following PSA Recurrence after Radical Prostatectomy (RP) 5,096 men treated with radical prostatectomy (RP) from 1982–2000 at Johns Hopkins 979 (19%) recurrences 379 with PSA doubling time (PSADT) data available 66 (17%) prostate cancer deaths Follow-up ◦10.3 y (range: 1–20 y) mean following surgery ◦6.8 y (range: 1–16 y) following PSA failure Freedland SJ et al. JAMA 2005;294(4):433-9.

Combined Risk Factors: 15-year of Cause-Specific Survival PSA-DT Biochemical Recurrence >3 years after RP Biochemical Recurrence ≤ 3 years after RP Gleason score <8 Gleason score ≥ 8 Gleason score <8 Gleason score ≥ 8 ≥ 15 mo94%87%81%62% 9.0 to 14.9 mo86%72%59%31% 3.0 to 8.9 mo59%30%16%1% <3.0 mo19%2%<1%

Natural History of Salvage XRT 1,540 men with PSA recurrence after RP all treated with salvage radiation therapy (XRT) Multicenter data 7.5 year median follow-up after RP Median pre-XRT PSA: 1.1 ng/ml Median pre-XRT PSADT: 6.9 months Stephenson AJ et al. J Clin Oncol 2007;25(15):

PSA Response to Salvage XRT Originally published by the American Society of Clinical Oncology. [Stephenson AJ et al: 25(15), 2007: ]

PSA Response to Salvage XRT PSA <0.5 ng/ml PSA 0.51 – 1.00 ng/ml PSA 1.01 – 1.50 ng/ml PSA >1.5 ng/ml Originally published by the American Society of Clinical Oncology. [Stephenson AJ et al: 25(15), 2007: ]

Salvage XRT and PCSM 635 men treated with RP at Johns Hopkins from 1982 to 2004 who had PSA recurrence 397 no salvage XRT 160 salvage XRT alone 78 salvage XRT + androgen deprivation therapy (ADT) Median f/u 6 years after recurrence; 9 years after RP 116 (18%) prostate cancer deaths Trock BJ et al. JAMA 2008;299(23):

Salvage XRT and PCSM Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. June 18;299(23): Copyright © (2008) American Medical Association. All rights reserved.

Predictors of PCSM after Salvage XRT Trock BJ et al. JAMA 2008;299(23): Variable No. deaths/ No. patients HR for PCSDp-value Years from RP to recurrence Year of surgery0.91<0.001 Path Gleason 8 vs. ≤72.26<0.001 PSA-DT <6 months No XRT XRT alone XRT + ADT 51/103 4/29 3/ (Reference) PSA-DT ≥6 months No XRT XRT alone XRT + ADT 38/294 14/131 6/ (Reference)

Early vs. Delayed ADT: Retrospective Analysis 4,967 men treated with RP within CPDR from ’88 to ’02 1,352 had PSA recurrence 355 had “early” ADT 997 had delayed/no ADT 103 metastasis Median follow-up 5.2 years after RP Patients who received salvage XRT were excluded from this analysis Moul JW et al. J Urol 2004;171(3)

Early vs. Delayed ADT: Retrospective Analysis Regardless of whether hormonal therapy was early or late, no difference was found overall. However, recall that the majority of this group of men were not going to progress to metastases. Moul JW et al. J Urol 2004;171(3)

Early vs. Delayed ADT: Retrospective Analysis Evaluated group of high-risk men: - Gleason score ≥8 or - PSA doubling time <12 months Showed significant benefit to early hormonal therapy - Delayed progression time to metastatic disease Moul JW et al. J Urol 2004;171(3)

Treating PSA Recurrence – Post Radiation No clear standard Most series are small ◦Most use cryotherapy or surgery ◦Highly selected men Long-term PSA control unclear ◦Some series report reasonable PSA control, though patients are highly selected

Treating PSA Recurrence – Post Radiation: Too Little Too Late? Surgery  fewer metastases than radiation ◦Zelefsky MJ et al. J Clin Oncol 2010;28(9): ◦“These results may be confounded by differences in the use and timing of salvage therapy” Time to secondary treatment after PSA rise: ◦Surgery: 13 months ◦Radiation: 69 months “Outcomes in high-risk cancers treated with EBRT could be further improved with the earlier administration of salvage therapy, local or systemic”

Clinical Trials for PSA Recurrence – Post Surgery RADICALS (next slide) TAX 3503 ◦PSADT < 9 months ◦1) ADT vs. 2) ADT + docetaxel ◦Progression free survival (includes PSA progression) RTOG 0534 ◦1) Prostate bed XRT vs. 2) prostate bed XRT + ADT (4-6 months) vs. 3) whole-pelvis + prostate bed XRT + ADT (4-6 months) ◦Primary outcome: Freedom from progression (includes PSA progression)

Clinical Trials for PSA Recurrence – Post Surgery: RADICALS Accrual on-going Primary outcome: Disease-specific survival ~4,000 men Results expected ~2020 Radical prostatectomy RADICALS - overall design Assess need: Is immediate Post-operative RT required? Uncertain RT timing RANDOMISATION Immediate RT Immediate RT Yes No Salvage RT policy Salvage RT policy Monitor on trialMonitor off trial Rise in PSANo rise in PSA Hormone duration RANDOMISATION On trial Off trial Treatment RT + 2yr HT Trial follow-up Outcomes measures RT + 6mo HT RT + no HT Outcomes measures Hormone duration RANDOMISATION RT + 2yr HT Trial follow-up Outcomes measures RT + 6mo HT RT + no HT Key

Clinical Trials for PSA Recurrence – Post Radiation None

Summary Determine risk of progression/death If high-enough risk, treat local first ◦XRT after surgery ◦Unknown after XRT If that fails, consider systemic therapy early for high- risk Low-risk can be safely watched for years On-going clinical trials will hopefully address many of these controversies